Paper

Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group.

Published 2000 · L H Silver

Survey of ophthalmology

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Study Snapshot

The optimal intraocular pressure-lowering concentration of brinzolamide is 1%, and when administered twice daily, it is well-tolerated by patients with primary open-angle glaucoma or ocular hypertension.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group.

References

Citations